Business Wire

CA-SAMBANOVA-SYSTEMS

26.10.2021 15:02:06 CEST | Business Wire | Press release

Share
SambaNova Announces ELEVAITE, a Membership Program Designed to Move the Global 2000 Towards an AI-Enabled Future; Now Open for Applications

SambaNova Systems , the company building the industry’s most advanced software, hardware and services to run AI applications, today announced that its AI membership program for the enterprise, ELEVAITE , is now open for applications. The program is designed to lead select cohorts of enterprises into the AI-enabled future leveraging SambaNova’s unmatched AI technology, solutions, expertise, and proven success while addressing the biggest challenges of starting and scaling an AI program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211026005330/en/

“The emergence of AI and its expected impact on the Global 2000 – akin to the impact of the internet – is upon us,” said Rodrigo Liang, co-founder and CEO of SambaNova. “For those with a desire to embrace the transformational power of AI, there are huge opportunities. With SambaNova ELEVAITE, enterprises will receive unmatched education and technical guidance that directly supports successful AI initiatives from conception to deployment, scalability, and ROI with market visibility for their technology leadership.”

Leaders across industries such as financial services, energy, manufacturing, healthcare, and more realize it is time to apply AI to their organization’s data resources. ELEVAITE is uniquely designed to accelerate selected cohort enterprises’ deployment of the most advanced and performant AI software, hardware, and services available for AI, machine learning, and deep learning.

As an ELEVAITE member, SambaNova teams will work with businesses to determine the most impactful AI technologies based on SambaNova’s experience and deep understanding of enterprise needs to deliver business impact. These include use cases for Natural Language Processing, Vision, and Recommendation.

“Enterprises well suited to participate in ELEVAITE are those that recognize the imperative to drive focus on new initiatives when looking to accelerate AI capabilities inside organizations,” said Marshall Choy, VP of Product at SambaNova. “Working together, ELEVAITE members and SambaNova will accelerate the deployment and scalability inside their enterprises.”

“ELEVAITE membership is designed to deliver unmatched education and awareness on a personal and cohort basis to accelerate enterprises’ transformation to an AI-Enabled organization,” said Amy Love, Chief Marketing Officer at SambaNova. “The program also furthers the market-leading standing of the selected companies by presenting them as leaders in their field.”

ELEVAITE members receive access to three categories of benefits:

  • Unmatched Collaboration for Success: By providing customized scoping, implementation and scaling of AI solutions, SambaNova’s dedicated technical and account leads will be with you every step of the way.
  • Institutionalized Skills and Knowledge : SambaNova founders, senior executives, board members, technologists, and industry luminaries will educate participating organizations to deliver the resources required to implement AI initiatives and develop new AI skills.
  • ELEVAITED Visibility Driving Enterprise Value: With access to the SambaNova VisionAIres program, participants can increase the visibility of their AI initiatives, develop thought leadership and enhance their company’s reputation through media exposure.

ELEVAITE reduces the risk for enterprises and commits to scalable deployment by providing access to unique SambaNova resources and knowledge to ensure they are successful with AI. Members have access to SambaNova’s turnkey platform, including Dataflow-as-a-Service™, an extensible AI services platform, and DataScale®, an integrated software and hardware platform delivering unrivaled performance, accuracy, scale and ease of use built on SambaNova’s Systems Reconfigurable Dataflow Architecture™. This eliminates the need for massive data science staffing, significantly reducing the cost of investment.

To learn more, schedule an executive conversation or to apply for the program, visit sambanova.ai/elevaite . The selection process will occur this fall and the first cohort program will begin in January 2022.

About SambaNova Systems:

SambaNova Systems is an AI innovation company that empowers organizations to deploy best-in-class solutions for natural language processing, computer vision, recommendation systems, and AI for science with confidence. SambaNova's flagship offering, Dataflow-as-a-Service™, helps organizations rapidly deploy AI in days, unlocking new revenue and boosting operational efficiency. SambaNova's DataScale® is an integrated software and hardware system using Reconfigurable Dataflow Architecture™, along with open standards and user interfaces. Headquartered in Palo Alto, California, SambaNova Systems was founded in 2017 by industry luminaries and hardware and software design experts from Sun/Oracle and Stanford University. Investors include SoftBank Vision Fund 2, funds and accounts managed by BlackRock, Intel Capital, GV, Walden International, Temasek, GIC, Redline Capital, Atlantic Bridge Ventures, Celesta, and several others. For more information, please visit us at sambanova.ai or contact us at info@sambanova.ai . Follow SambaNova Systems on LinkedIn .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 15:30:00 CEST | Press release

Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet needThe collaboration will augment Merck’s efforts to pursue precision medicine-defined indicationsNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Resea

Beyond the ‘Dumb Pipe’: How Agentic AI and Sovereign Networks Are Redefining Connectivity23.6.2026 14:46:00 CEST | Press release

The global connectivity market is shifting. With traditional European telecom growth slowing to 2-3% by 2029, businesses must adapt through Agentic AI, critical communications, and digital sovereignty. To remain competitive, operators should move beyond infrastructure toward an API-driven economy. These trends took center stage at Comarch User Group 2026. The conference hosted over 700 partners from 53 countries, including 201 connectivity experts, highlighting how companies can thrive in regulated environments. As telecom growth slows, demand for broader connectivity solutions across satellite, logistics, and critical communications is surging. Operators must abandon the old 4G “dumb pipe” model, where they act merely as network providers charging only for raw data transmission, for an API-driven economy with programmable network quality, securely integrating 5G with new satellite and IoT ecosystems. - Marcin Kaleta, CEO at Comarch Communications Putting Agentic AI in the Driver's Sea

Mary Kay Extends Winning Streak With Fourth Year as #1 in Global Direct Selling Beauty23.6.2026 14:03:00 CEST | Press release

Euromonitor International Recognizes Mary Kay’s Sustained Leadership In Skin Care And Color Cosmetics Mary Kay Inc., the iconic beauty and entrepreneurship company, has once again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International, sustaining its legacy of excellence for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623487381/en/ Mary Kay Inc., the iconic beauty and entrepreneurship company, for the fourth year in a row has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International. (Image Credit: Mary Kay Inc.) “Earning the #1 global ranking from Euromonitor for the fourth consecutive year comes as a powerful endorsement of the impact of our Independent Beauty Consultants around the world who drive our success every day,” said Ryan Rogers, Chief Executive Officer of Mary Kay

Kobie 2026 Heart of Loyalty Report Reveals Growing Gap Between Consumer Expectations and Brand Loyalty Strategies23.6.2026 14:00:00 CEST | Press release

Global study finds consumers are more ready for AI, more willing to share data, and more motivated by recognition and shared values than many brands realize Kobie, a global leader in loyalty technology and services, today released its 2026 Heart of Loyalty Report, which surveyed both consumers and practitioners, revealing significant gaps between consumer expectations and brand loyalty strategies across AI adoption, data sharing, recognition, advocacy, and community engagement. Kobie's 2026 Heart of Loyalty Report found that: 57% of consumers are willing to engage with AI-powered brand experiences, yet 56% of loyalty practitioners believe customers are not ready for AI. 77% of consumers want recognition from brands, but only 55% feel seen as individuals. 72% of consumers say they would refer a brand without an incentive, yet many referral strategies remain heavily dependent on rewards. Rewards are the strongest driver of willingness to share personal data, yet only 65% of practitioners

Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release

Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye